Keymed Biosciences Inc. (HKG:2162)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
81.55
+1.95 (2.45%)
Sep 30, 2026, 4:08 PM HKT

Keymed Biosciences Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Keymed Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $103.88. The average 1-year stock price forecast is 27.38% higher than the current stock price, while the lowest is $90.31 (+10.74%) and the highest is $119.09 (+46.03%).

Price Target: $103.88 (+27.38%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$90.31$103.88$104.22$119.09
Change+10.74%+27.38%+27.80%+46.03%
* Price targets were last updated on Aug 26, 2026.

Analyst Ratings

The average analyst rating for Keymed Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy66781010
Buy344555
Hold000000
Sell000000
Strong Sell000000
Total91011131515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
SDIC Securities
No rating
SDIC Securities
Buy
Maintains
$90.37
BuyMaintains$90.37+10.82%Aug 26, 2026
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$98.00
BuyMaintains$98.00+20.17%Aug 25, 2026
Unknown Analyst
SPDB
No rating
SPDB
Buy
Maintains
$108.30
BuyMaintains$108.30+32.80%Aug 25, 2026
Unknown Analyst
Daiwa
No rating
Daiwa
Buy
Maintains
$101.00
BuyMaintains$101.00+23.85%Aug 12, 2026
Unknown Analyst
Guotai Haitong
No rating
Guotai Haitong
Buy
Maintains
$138.91
BuyMaintains$138.91+70.34%Jul 10, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.68B
from 716.31M
Increased by 134.79%
Revenue Next Year
2.15B
from 1.68B
Increased by 27.60%
EPS This Year
3.27
from -1.81
EPS Next Year
0.35
from 3.27
Decreased by -89.30%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
110.27M100.06M354.10M428.12M716.31M1.68B
Revenue Growth
--9.26%253.87%20.91%67.31%134.79%
Gross Profit
93.07M97.48M317.22M415.92M627.06M1.45B
Gross Margin
84.40%97.42%89.59%97.15%87.54%85.94%
Operating Income
-360.50M-544.49M-457.43M-626.09M-631.05M317.92M
Net Income
-3.89B-308.12M-359.36M-515.24M-522.64M672.49M
EPS
-----1.813.27
Forward PE
-----21.28
Free Cash Flow
-----1.05B942.00M
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High2.7B
Avg1.7B
Low1.1B

Revenue Growth

Revenue Growth202620272028
High
282.9%
Avg
134.8%
Low
51.6%

EPS Forecast

EPS202620272028
High3.77
Avg3.27
Low2.69

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-